BioCardia, Inc.BCDAEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
BioCardia, Inc. is a clinical-stage biotechnology company specializing in regenerative therapies for cardiovascular diseases. It develops cell and gene therapy candidates targeting heart failure, myocardial infarction, and other cardiac disorders, serving patients across North America and global cardiology care segments, with a focus on improving long-term cardiac function for underserved patient populations.
What changed in BioCardia, Inc.'s 10-K — 2022 vs 2023
No meaningful paragraph-level changes detected in the compared sections. Either the two filings are nearly identical or the sections did not parse.